Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy.

Fifty patients with small-cell lung cancer (SCLC) were treated with teniposide (VM26) at 120 to 140 mg/m2 on days 1, 3, and 5, every 3 weeks. Twelve elderly patients were administered VM26 as first-line chemotherapy. Toxicity was manageable, myelosuppression being the major side effect. The response rate for 44 evaluable patients was 34% (36% for untreated patients); the median durations of response and survival were 230 and 208 days, respectively. Effectiveness of prior chemotherapy and time from last administration was found to influence patient response to VM26: 42% of responders to prior chemotherapy responded to VM26, while 0% of the nonresponders to prior chemotherapy responded to the new agent. Moreover, among patients pretreated with chemotherapy, 12% of those recently treated (earlier chemotherapy ending less than or equal to 2.6 months before administration of VM26) responded to VM26, while 53% of patients treated greater than 2.6 months earlier responded to VM26. Survival was influenced by common prognostic factors (performance status, weight loss, prior chemotherapy exposure). Selection of pretreated patients by type of exposure to prior chemotherapy may help in the testing of new drugs in this disease.

[1]  G. Giaccone,et al.  Reinduction chemotherapy in small cell lung cancer. , 1987, European journal of cancer & clinical oncology.

[2]  G. Giaccone,et al.  Teniposide in the treatment of non-small cell lung carcinoma. , 1987, Cancer treatment reports.

[3]  E. Eisenhauer,et al.  Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study. , 1986, Cancer treatment reports.

[4]  N. Mulder,et al.  High-dose teniposide for refractory malignancies: a phase I study. , 1986, Cancer treatment reports.

[5]  H. Hansen,et al.  Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Mann,et al.  Etoposide and cisplatin salvage chemotherapy for small cell lung cancer. , 1985, Cancer treatment reports.

[7]  M. Zucchetti,et al.  Pharmacokinetics of teniposide in patients with ovarian cancer. , 1985, Cancer treatment reports.

[8]  J. Yarnold,et al.  Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. , 1985, Cancer treatment reports.

[9]  B. Leyland-Jones,et al.  Teniposide: a review of 12 years of experience. , 1984, Cancer treatment reports.

[10]  D. Ihde.  Current status of therapy for small cell carcinoma of the lung , 1984, Cancer.

[11]  H. Hansen,et al.  Phase II study of teniposide in small cell carcinoma of the lung. , 1984, Cancer treatment reports.

[12]  D. Ettinger,et al.  Phase II study of PALA, amsacrine, teniposide, and zinostatin in small cell lung carcinoma (EST 2579). , 1984, Cancer treatment reports.

[13]  D. Osoba,et al.  VP‐16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer , 1984, Cancer.

[14]  J. Hainsworth,et al.  High-dose etoposide as single-agent chemotherapy for small cell carcinoma of the lung. , 1983, Cancer treatment reports.

[15]  M. Broggini,et al.  Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice. , 1983, Cancer treatment reports.

[16]  P. Bunn,et al.  Small-cell carcinoma of lung: reinduction therapy after late relapse. , 1983, Annals of internal medicine.

[17]  J. Ducore,et al.  Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts. , 1983, Cancer research.

[18]  M. Tattersall,et al.  Treatment of small cell bronchogenic carcinoma with VM-26. , 1979, Cancer treatment reports.

[19]  P. Bunn,et al.  Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. , 1979, Cancer treatment reports.

[20]  R. Fisher,et al.  Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. , 1979, Annals of internal medicine.

[21]  L. Baker,et al.  VM26 (NSC-122819): a clinical study in advanced cancer of the lung and ovary. , 1978, European journal of cancer.

[22]  H. Senn,et al.  VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. , 1978, Cancer treatment reports.

[23]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[24]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .